This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
VILLA GUARDIA (COMO), Italy, March 21, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced today that it will report its fourth quarter and full year 2012 financial results on Thursday, March 28, 2013, and hold a conference call and live webcast 7:00 a.m. ET / 12:00 noon CET to discuss the results and provide a business update. A press release detailing the results will be issued prior to the call.
To participate in the call, interested parties may dial 1-866-966-9439 (US toll-free) or +44(0)1452-555-566 (international/toll) to register ten minutes before the call is scheduled to begin, using the Conference ID 27052144. The call will also be broadcast live on the internet at
http://www.gentium.com and will be archived for replay for 30 days. The replay can be accessed on the Company's website,
http://www.gentium.com or at 1-866-247-4222 (US toll-free) or +44(0)1452-550-000 (international/toll) using the Conference ID 27052144
Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency, both to treat and to prevent VOD, as well as Fast Track Designation by the U.S. FDA to treat VOD.
The Gentium S.p.A. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=12669Cautionary Note Regarding Forward-Looking Statements This release contains "forward-looking statements" that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of Gentium's securities. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Form 20-F filed with the Securities and Exchange Commission under the caption "Risk Factors."